Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Maturitas. 2021 Sep 5;154:13–19. doi: 10.1016/j.maturitas.2021.09.002

Table 4.

Incident cancers by treatment group in intention to treat population

Oral E2 plus Vaginal P4 (262 women) Placebo (264 women) Proportion Difference
Total cancer (N women) 11, 4.2% (2.1%, 7.4%) 12, 4.5% (2.4%, 7.8%) −0.3% (−3.8%, 3.1%)
Breast cancer 6, 2.3% (0.8%, 4.9%) 6, 2.3% (0.8%, 4.9%) 0% (−2.5%, 2.5%)
Colorectal cancer 3, 1.1% (0.2%, 3.3%) 1, 0.3% (0%, 2.1%) −0.8% (−0.7%, 2.3%)
Endometrial cancer 2, 0.8% (0.1%, 2.7%) 1, 0.4% (0%, 2.1%) 0.4% (−0.9%, 1.7%)
Ovarian cancer 0, 0% (0%, 1.4%) 1, 0.4% (0%, 2.1%) −0.4% (−1.1%, 0.4%)
Pancreatic cancer 0, 0% (0%, 1.4%) 1, 0.4% (0%, 2.1%) −0.4% (−1.1%, 0.4%)
Stomach cancer 0, 0% (0%, 1.4%) 1, 0.4% (0%, 2.1%) −0.4% (−1.1%, 0.4%)
Uterine cancer** 0, 0% (0%, 1.4%) 1, 0.4% (0%, 2.1%) −0.4% (−1.1%, 0.4%)
Lung cancer** 0, 0% (0%, 1.4%) 1, 0.4% (0%, 2.1%) −0.4% (−1.1%, 0.4%)
Months to first cancer diagnosis, median (IQR) 40 (34.0–48.0) 17 (4.5–32.0) 0.93*

Data reported as number of women, proportion, 95%confidence interval of proportion

E2=estradiol, P4=progesterone

*

Log rank test was used to compare the time until the first cancer (in months) by treatment group.

**

Uterine and lung cancer occurred synchronously within the same participant